Inhibitors

Novartis to Acquire Myricx Bio for Up to $1.5 Billion

The deal adds a novel N‑myristoyltransferase inhibitor payload platform and two preclinical ADC candidates to Novartis and shifts the next test to clinical validation and regulatory close.